<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04139954</url>
  </required_header>
  <id_info>
    <org_study_id>TRASD</org_study_id>
    <nct_id>NCT04139954</nct_id>
  </id_info>
  <brief_title>Observational Registry of Patients With Rheumatoid Arthritis /Spondyloarthritis Using Biological or Targeted Synthetic DMARDs</brief_title>
  <acronym>BioSTaR</acronym>
  <official_title>Observational Registry (BioSTaR) Including Demographic and Clinical Data of Patients Diagnosed With Rheumatoid Arthritis and Spondyloarthritis Using a Biological and Targeted Synthetic Disease Modifying Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turkish League Against Rheumatism</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turkish League Against Rheumatism</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators aimed to observe the examination findings, laboratory findings
      and drugs used in routine polyclinic controls of the participants using biological and
      targeted synthetic disease-modifying antirheumatic drug (DMARD) and the doses and side
      effects of these drugs. The aim of this registry is to evaluate the real-life data of
      participants receiving these medications. Analysis of treatment follow-up, drug changes,
      causes of change, treatment-related paradoxic / immune reactions, compliance with adult
      vaccination programs, nutritional profiles, presence of metabolic syndrome, fertility status,
      pregnancy outcomes, and vitamin D levels will be recorded in the outpatient clinic.
      Rheumatoid Arthritis Impact of Disease, Psoriatic Arthritis Impact of Disease (RAID and PSAID
      indexes), Work Productivity and Activity Impairment Questionnaire (WPAI), drug compliance,
      central sensitization and fall risk will be evaluated with verbal evaluation forms performed
      at policlinic controls in patients with spondyloarthritis and rheumatoid arthritis. It is
      planned to conduct scientific analyzes and publish on various subjects from the recorded
      information on this registration system.

      Patients using biological and targeted synthetic DMARD treatments are closely monitored and
      evaluated in many ways due to the risk profiles and various characteristics of the drugs.
      With this registry system, it is aimed to evaluate the real-life data of the participants
      using these drugs. Real-life data are very valuable in monitoring the disease and the drugs.

      The study is observational and there is no expected risk since no intervention is planned.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, investigators aimed to observe the examination findings, laboratory findings
      and drugs used in routine polyclinic controls of the participants using biological and
      targeted synthetic disease-modifying antirheumatic drug (DMARD) and the doses and side
      effects of these drugs. The aim of this registry is to evaluate the real-life data of
      participants receiving these medications. Analysis of treatment follow-up, drug changes,
      causes of change, treatment-related paradoxic / immune reactions, compliance with adult
      vaccination programs, nutritional profiles, presence of metabolic syndrome, fertility status,
      pregnancy outcomes, and vitamin D levels will be recorded in the outpatient clinic.
      Rheumatoid Arthritis Impact of Disease, Psoriatic Arthritis Impact of Disease (RAID and PSAID
      indexes), Work Productivity and Activity Impairment Questionnaire (WPAI), drug compliance,
      central sensitization and fall risk will be evaluated with verbal evaluation forms performed
      at policlinic controls in patients with spondyloarthritis and rheumatoid arthritis. It is
      planned to conduct scientific analyzes and publish on various subjects from the recorded
      information on this registration system.

      Patients using biological and targeted synthetic DMARD treatments are closely monitored and
      evaluated in many ways due to the risk profiles and various characteristics of the drugs.
      With this registry system, it is aimed to evaluate the real-life data of the participants
      using these drugs. Real-life data are very valuable in monitoring the disease and the drugs.

      Planned studies are:

      ROMATOID ARTHRITIS CLINICAL DEMOGRAPHIC ASSESSMENT / DISEASE EFFECT / DRUGS

        -  SPONDYLOARTHRITIS CLINICAL DEMOGRAPHIC EVALUATION / DISEASE EFFECT / DRUGS

        -  COMORBIDITY IN ROMATOID ARTHRITIS

        -  COMORBIDITY IN SPONDYLOARTHRITIS

        -  RE ACTIVITATION AND SAFETY MONITORING IN VIRAL HEPATITIS

        -  TREATMENT PARADOXIC / IMMUNE REACTIONS (SYSTEMIC AUTOIMMUNE, ARTHRITIS, HEMATOLOGIC,
           NEUROLOGIC, PULMONARY, OPHTHALMOLOGICAL, INFLAMMATORY BOWEL DISEASE, LIVER, CUTANEOUS,
           OTHER)

        -  WORK FORCE LOSS IN AXIAL SPONDYLOARTHRITIS

        -  WORK FORCE LOSS IN PSORIATIC ARTHRITIS

        -  WORK FORCE LOSS IN ROMATOID ARTHRITIS

        -  PREGNANCY / FERTILITY OUTCOMES

        -  TUBERCULOSIS MONITORING

        -  DRUG SWITCH ANALYSIS

        -  THROID DISEASE IN EARLY AND ESTABLISHED ROMATOID ARTHRITIS (AUTOIMMUNE THROIDITIS,
           MALIGNITY etc)

        -  TREATMENT COMPLIANCE IN RHEUMATIC DISEASES

        -  ADULT IMMUNIZATION PROGRAM IN RHEUMATIC DISEASES

        -  METABOLIC SYNDROME ASSESSMENT

        -  CARDIOVASCULAR RISK ASSESSMENT

        -  FALL / FRACTURE AND RELATED VARIABLES IN RHEUMATIC DISEASES

        -  VITAMIN D STATUS IN RHEUMATIC DISEASES

        -  CENTRAL SENSITIZATION AND PAIN IN ROMATOID ARTHRITIS AND SPONDYLOARTROPATHIES AND
           RELATED VARIABLES The study is observational and there is no expected risk since no
           intervention is planned.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease activity RA</measure>
    <time_frame>24 weeks</time_frame>
    <description>DAS 28 score will be calculated (Sensitive and swollen joints, VAS pain score, patient's global assessment and CRP / ESH values will be used for scoring)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity- SpA1</measure>
    <time_frame>24 weeks</time_frame>
    <description>ASDAS score will be calculated (Sensitive and swollen joints, VAS pain score, patient's global assessment and CRP / ESH values will be used for scoring)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity-SpA2</measure>
    <time_frame>24 weeks</time_frame>
    <description>BASDAI score will be calculated</description>
  </primary_outcome>
  <other_outcome>
    <measure>WPAI (Work Productivity and Activity Impairment Questionnaire)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Work Productivity and Activity Impairment Questionnaire:</description>
  </other_outcome>
  <other_outcome>
    <measure>RAID (Rheumatoid Arthritis Impact of Disease Questionnaire)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Rheumatoid Arthritis Impact of Disease Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>PSAID (Psoriatic Arthritis Impact of Disease Questionnaire)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Psoriatic Arthritis Impact of Disease Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>DN-4 (Douleur Neuropathic 4 Questionnaire) questions)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Neuropathic pain questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiovascular disease risk</measure>
    <time_frame>1 year</time_frame>
    <description>HDL and LDL cholesterol (mg/dl) levels from records , hypertension and diabetes history will be evaluated</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 (Short form 36)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Quality of life questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>HAQ (Health assessment questionnaire)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Functional assessment, Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>ASAS-HI (ASAS Health Index)</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>ASAS Health Index</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibromyalgia and central sensitization</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Fibromyalgia criteria and central sensitization will be questioned</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics -Age</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>Age, years</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics -Gender</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>female/ male</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics- smoking</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>Amount of smoking (packet-year)</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics- alcohol use</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>How much and how often drink</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics- education</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>Illiterate, literate, years of training</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics- fertility and pregnancy history</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>In her history; pregnancy, abortus, stillbirth, live birth, anomalies number</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics, body mass index (kg/m2)</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Height (cm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics, body mass index (kg/m2)</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Weight (kg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Demographic characteristics, menopause</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>presence of menopause</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination hand deformities,</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>subluxation, deviation, swan neck, button marrow deformities in hand examination</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination hand deformities,</measure>
    <time_frame>It will be evaluated at the beginning of the study</time_frame>
    <description>Subcutanea nodules</description>
  </other_outcome>
  <other_outcome>
    <measure>Lung involvement</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Known pulmonary involvement, pulmonary function test and computed tomography results</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological involvement</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Existing entrapment neuropathy, central involvement will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory- Urea</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Urea levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory- creatinine</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Creatinine levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory- liver function tests</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Liver function tests from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-vitamin D</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Vitamin D levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-hemoglobin</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>hemoglobin levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-leukocyte</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>leukocyte levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-platelet</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>platelet levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-Rheumatoid factor (RF)</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>Rheumatoid factor (RF) levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-anticyclic citrullinated peptide (Anti CCP)</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>Anti CCP levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-Lipid profile</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>LDL, HDL, Triglycerin, Cholesterol levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-hepatitis serology</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>HBs Ag, Anti HBs, HBc Ag, HBe Ag, Anti HBC levels from records, receiving antiviral treatment for hepatitis, hepatitis reactivation history will be questioned</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory-HIV serology</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Anti HIV levels from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Imaging findings- X Ray</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>Hand wrist and pelvis X ray from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Imaging findings- magnetic resonance imaging</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>Sacroiliac joint MRI from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Imaging findings- Ultrasound</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>Hand ultrasound from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Imaging findings- Bone Mineral density</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Bone Mineral density from records</description>
  </other_outcome>
  <other_outcome>
    <measure>Comorbidity</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>Presence of hypertension, diabetes, autoimmune thyroiditis, metabolic syndrome, coronary artery disease, chronic renal failure,pulmonary dieses, gastric ulcer, anxiety, depression, surgeries, cancer from patient records</description>
  </other_outcome>
  <other_outcome>
    <measure>Fall risk</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>The number of falls in the last year, the feeling of walking imbalance and the fear of falling and fracture history</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of tuberculosis</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>PPD / quantiferon result and INH use before drug initiation</description>
  </other_outcome>
  <other_outcome>
    <measure>Vaccination program</measure>
    <time_frame>It will be evaluated at the beginning</time_frame>
    <description>Applied hepatitis, tuberculosis, pneumonia, influenza vaccination programme</description>
  </other_outcome>
  <other_outcome>
    <measure>Drugs</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>All drugs and doses previously used in relation to rheumatic disease will be questioned. Side effects, autoimmune/ paradoxic reactions and switching of drugs from records will be checked</description>
  </other_outcome>
  <other_outcome>
    <measure>BASMI</measure>
    <time_frame>an average of 2 year</time_frame>
    <description>Bath Ankylosing Spondylitis Metrology Index</description>
  </other_outcome>
  <other_outcome>
    <measure>MASES</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Maastricht Ankylosing Spondylitis Enthesitis Score</description>
  </other_outcome>
  <other_outcome>
    <measure>PASI</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>The Psoriasis Area Severity Index</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis and Spondyloarthritis</arm_group_label>
    <description>Patients using Biological or Targeted Synthetic DMARDs</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention in the study</intervention_name>
    <description>There is no intervention in the study</description>
    <arm_group_label>Rheumatoid arthritis and Spondyloarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients followed in rheumatology and physical
        medicine and rehabilitation clinics in tertiary hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical diagnosis with rheumatoid arthritis or spondyloarthritis Receiving biological or
        targeted synthetic DMARD treatment

        Exclusion Criteria:

        Aged under 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatice Bodur, Prof Dr</last_name>
    <role>Study Director</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Şebnem Ataman, Prof Dr</last_name>
    <role>Study Director</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatma G Yurdakul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Özgür Akgül, AssocProf Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erhan Çapkın, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fatih Çay, AssocProf Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Remzi Çevik, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuncay Duruöz, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Feride Göğüş, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gülcan Gürer, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayhan Kamanlı, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meltem Alkan Melikoğlu, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aylin Rezvani, AssocProf</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>İlhan Sezer, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>İsmihan Sunar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_official>
    <last_name>İlker Yağcı, Prof Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turkish League Against Rheumatism</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatma G Yurdakul, MD</last_name>
    <phone>+905059254214</phone>
    <email>fatmagulonder@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hatice Bodur, Prof Dr</last_name>
    <phone>+905054848496</phone>
    <email>haticebodur@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankara Numune Training and Education Hospital, Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hatice Bodur, Prof Dr</last_name>
      <phone>+905054848496</phone>
      <email>haticebodur@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fatma G Yurdakul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ankara University, Faculty of Medicine, Department of Rheumatology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Şebnem Ataman, Prof Dr</last_name>
      <phone>+905322711076</phone>
      <email>ataman.sebnem@gmail.com</email>
    </contact>
    <investigator>
      <last_name>İsmihan Sunar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gazi University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Department of Rheumatology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feride Göğüş, Prof Dr</last_name>
      <phone>05322501164</phone>
      <email>feride_g@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akdeniz University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İlhan Sezer</last_name>
      <phone>05055402273</phone>
      <email>drilhan@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antalya Training and Research Hospital Physical Medicine and Rehabilitation Clinic</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatih Çay, Assoc Prof</last_name>
      <phone>05322509147</phone>
      <email>drfatihcay@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Adnan Menderes University, Faculty of Medicine, Department of Rheumatology</name>
      <address>
        <city>Aydın</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gülcan Gürer, Prof Dr</last_name>
      <phone>05334595107</phone>
      <email>gurergulcan@yahoo.com.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dicle University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Diyarbakır</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remzi Çevik, Prof Dr</last_name>
      <phone>05322282856</phone>
      <email>ftremzi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Medipol University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aylin Rezvani, Assoc Prof</last_name>
      <phone>05336684078</phone>
      <email>rezvani.aylin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marmara University Faculty of Medicine Department of Physical Medicine and Rehabilitation, Department of Rheumatology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuncay Duruöz, Prof Dr</last_name>
      <phone>05335121548</phone>
      <email>tuncayduruoz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marmara University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İlker Yağcı, Prof Dr</last_name>
      <phone>05334597155</phone>
      <email>drilkery@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Celal Bayar University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Özgür Akgül, Assoc Prof</last_name>
      <phone>05515986299</phone>
      <email>ozgur.akgul.md@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sakarya University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Sakarya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayhan Kamanlı, Prof Dr</last_name>
      <phone>05387046906</phone>
      <email>akamanli@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atatürk University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Sivas</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meltem Alkan Melikoğlu, Prof Dr</last_name>
      <phone>05326934469</phone>
      <email>mamelikoglu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karadeniz Technical University Faculty of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erhan Çapkın, Prof Dr</last_name>
      <phone>05052344258</phone>
      <email>drcapkin@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turkish League Against Rheumatism</investigator_affiliation>
    <investigator_full_name>Fatma Gül Yurdakul</investigator_full_name>
    <investigator_title>Clinical Associate Professor (Fatma Gül Yurdakul)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the collected data will be shared with investigators of the study</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After the end of the study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

